A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Allowed: BCL2 rearrangement

Allowed: MYC rearrangement

Must have received: combination chemotherapy (rituximab, anthracycline, alkylating agent, steroids) — first-line

first-line combination chemotherapy regimen containing rituximab, anthracycline, an alkylating agent, and steroids

Cannot have received: CAR-T cell therapy

Participants must not have prior CAR-T

Cannot have received: radiotherapy

radiotherapy ≤ 4 weeks

Cannot have received: systemic anticancer treatment

systemic anticancer treatment ≤ 5 half-lives or 4 weeks

Cannot have received: allogeneic stem cell transplant

Exception: only applicable to BMS-986458 single agent or rituximab combination cohorts

allogeneic SCT ≤ 6 months (only applicable to BMS-986458 single agent or rituximab combination cohorts)

Cannot have received: autologous stem cell transplant

autologous SCT ≤ 3 months prior to study intervention initiation

Cannot have received: solid organ transplantation

Exception: only in BMS-986458 + T-cell engager combination cohorts

Participants must not have prior alloSCT or solid organ transplantation